BioCentury
ARTICLE | Company News

Rexahn, National Cancer Institute deal

July 27, 2015 7:00 AM UTC

Rexahn said the NCI’s Nanotechnology Characterization Laboratory (NCL) accepted RX-21101 for a preclinical characterization program, which Rexahn said will facilitate movement of the cancer compound ...